Cargando…

Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?

No established second-line chemotherapy is available for patients with advanced gastric cancer failing to respond or progressing to first-line chemotherapy. However, 20–40% of these patients commonly receive second-line chemotherapy. We evaluated the influence of clinico-pathologic factors on the su...

Descripción completa

Detalles Bibliográficos
Autores principales:	Catalano, V, Graziano, F, Santini, D, D'Emidio, S, Baldelli, A M, Rossi, D, Vincenzi, B, Giordani, P, Alessandroni, P, Testa, E, Tonini, G, Catalano, G
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2579675/ https://www.ncbi.nlm.nih.gov/pubmed/18971936 http://dx.doi.org/10.1038/sj.bjc.6604732

Ejemplares similares

Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin- and/or irinotecan-based chemotherapy
por: Catalano, V, et al.
Publicado: (2009)

Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trial
por: Santini, D, et al.
Publicado: (2006)

Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy
por: Graziano, F, et al.
Publicado: (2008)

“Short Course” of Nonpegylated Liposomal Doxorubicin Plus Paclitaxel and Trastuzumb as Primary Systemic Therapy for Operable and Locally-Advanced Breast Cancer: A Phase II Study (PacLiDox 07)
por: Rossi, D., et al.
Publicado: (2011)

A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancer
por: Graziano, F, et al.
Publicado: (2003)

Early and Complete Response of Bone Metastases, Documented by FDG-PET/CT Scan, in a Patient With NSCLC
por: Rossi, David, et al.
Publicado: (2012)

Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients
por: Graziano, F, et al.
Publicado: (2002)

Genetic modulation of the interleukin 6 (IL-6) system in patients with advanced gastric cancer: a background for an alternative target therapy
por: Ruzzo, Annamaria, et al.
Publicado: (2014)

Potential role and chronology of abnormal expression of the Deleted in Colon Cancer (DCC) and the p53 proteins in the development of gastric cancer
por: Graziano, Francesco, et al.
Publicado: (2001)

A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer
por: Cascinu, S, et al.
Publicado: (2001)

Over-D1 dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients
por: Scartozzi, M, et al.
Publicado: (2005)

An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiation
por: Cascinu, S, et al.
Publicado: (2002)

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2011)

Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer : A low cost effective regimen
por: Cascinu, S, et al.
Publicado: (2002)

Epicardial adipose tissue and atrial fibrillation: The other side of the coin
por: Leggio, Massimo, et al.
Publicado: (2017)

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2009)

Steroid-refractory immune related hepatitis may hide viral re-activation
por: Citarella, Fabrizio, et al.
Publicado: (2020)

Next Generation Sequencing Approach in a Prenatal Case of Cardio-Facio-Cutaneus Syndrome
por: Mucciolo, Mafalda, et al.
Publicado: (2016)

Procalcitonin as diagnostic marker of infection in solid tumors patients with fever
por: Vincenzi, B., et al.
Publicado: (2016)

Impact of Signet-Ring Cell Histology in the Management of Patients with Non-Metastatic Gastric Cancer: Results from a Retrospective Multicenter Analysis Comparing FLOT Perioperative Chemotherapy vs. Surgery Followed by Adjuvant Chemotherapy
por: Giampieri, Riccardo, et al.
Publicado: (2023)

First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
por: Tonini, Giuseppe, et al.
Publicado: (2009)

TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy
por: Graziano, Francesco, et al.
Publicado: (2020)

Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma
por: Simonetti, Sonia, et al.
Publicado: (2022)

RapidResa Polymyxin Acinetobacter NP(®) Test for Rapid Detection of Polymyxin Resistance in Acinetobacter baumannii
por: Bouvier, Maxime, et al.
Publicado: (2021)

Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial
por: Vincenzi, B, et al.
Publicado: (2006)

Atrial fibrillation and percutaneous coronary intervention: Are newer antithrombotic agents better for older patients?
por: Leggio, Massimo, et al.
Publicado: (2018)

Cetuximab in small bowel adenocarcinoma: a new friend?
por: Santini, D, et al.
Publicado: (2010)

Do co-morbidities, frailty and functional status identify patients who may not benefit from ICD therapy?
por: Wilson, D G, et al.
Publicado: (2023)

The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients
por: Pantano, Francesco, et al.
Publicado: (2013)

Targeting bone metastases starting from the preneoplastic niche: home sweet home
por: Santini, Daniele, et al.
Publicado: (2011)

Coronavirus Disease 2019 or Lung Cancer: What Should We Treat?
por: Russano, Marco, et al.
Publicado: (2020)

Identifying patients who may benefit from treatment
por: Abacı, Adnan
Publicado: (2018)

Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer
por: Santini, Daniele, et al.
Publicado: (2006)

Second line of treatment for HER2-positive gastric cancer: an evolving issue
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Osteoblasts Promote Prostate Cancer Cell Proliferation Through Androgen Receptor Independent Mechanisms
por: Ribelli, Giulia, et al.
Publicado: (2021)

Hypertensive response to exercise and exercise training in hypertension: odd couple no more
por: Caldarone, Elisa, et al.
Publicado: (2017)

Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer
por: Tonini, Giuseppe, et al.
Publicado: (2013)

Ultrasonographic evaluation of placental cord insertion at different gestational ages in low-risk singleton pregnancies: a predictive algorithm
por: Padula, F, et al.
Publicado: (2016)

Evidence-based guidelines: Improving AGREEment on consistence evaluation
por: Vincenzi, Bruno, et al.
Publicado: (2012)

Cabozantinib and apixaban: an hitherto unreported interaction
por: Santini, Daniele, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_b7e87q6dmt6ftso74olrqth9tp